<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=17087&amp;modal=1&amp;valnames=primary_outcome&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="481868" class="table-">
                
                <td>Oct. 25, 2023, 4 a.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            SSA - Ph 1 dose finding, percentage of participants reporting adverse events;SSA - Ph 1 dose finding, percentage of participants reporting serious adverse events;SSA - Ph 1 dose finding, percentage of participants reporting systemic events;SSA - Ph 2/3 selected dose, noninferiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron XBB.1.5-neutralizing titers in participants ≥2 to &lt;5 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron XBB.1.5-neutralizing titers in participants ≥6 months to &lt;2 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to seroresponse rate to the Omicron XBB.1.5 strain in participants ≥2 to &lt;5 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to seroresponse rate to the Omicron XBB.1.5 strain titers in participants ≥6 months to &lt;2 years of age;SSA - Ph 2/3 selected dose, percentage of participants reporting adverse events;SSA - Ph 2/3 selected dose, percentage of participants reporting local reactions;SSA - Ph 2/3 selected dose, percentage of participants reporting serious adverse events;SSA - Ph 2/3 selected dose, percentage of participants reporting systemic events;SSB - noninferiority with respect to seroresponse rate to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - percentage of participants reporting adverse events;SSB - percentage of participants reporting serious adverse events;SSB - percentage of participants reporting systemic events;SSB - superiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding - geometric mean fold rise elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding - geometric mean titers elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding, percentage of participants reporting adverse events;SSC - Ph 1 dose finding, percentage of participants reporting serious adverse events;SSC - Ph 1 dose finding, percentage of participants reporting systemic events;SSC - Ph 1 dose finding - percentage of participants with seroresponse elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSD - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥5 to &lt;12 years of age;SSD - percentage of participants reporting adverse events;SSD - percentage of participants reporting serious adverse events;SSD - percentage of participants reporting systemic events;SSD - the ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥5 to &lt;12 years of age;SSE - noninferiority with respect to ratio of the geometric mean of SARS-CoV-2 reference strain-neutralizing titers in participants ≥5 to &lt;12 years of age;SSE - noninferiority with respect to seroresponse rate to the reference strain in participants ≥5 to &lt;12 years of age;SSE - percentage of participants reporting adverse events;SSE - percentage of participants reporting serious adverse events;SSE - percentage of participants reporting systemic events;Substudy A (SSA) - Ph 1 dose finding, percentage of participants reporting local reactions;Substudy B (SSB) - percentage of participants reporting local reactions;Substudy C (SSC) - Ph 1 dose finding, percentage of participants reporting local reactions;Substudy D (SSD) - percentage of participants reporting local reactions;Substudy E (SSE) - percentage of participants reporting local reactions
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            SSA - Ph 1 dose finding, percentage of participants reporting adverse events;SSA - Ph 1 dose finding, percentage of participants reporting serious adverse events;SSA - Ph 1 dose finding, percentage of participants reporting systemic events;SSA - Ph 2/3 selected dose, noninferiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron XBB.1.5-neutralizing titers in participants ≥2 to &lt;5 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron XBB.1.5-neutralizing titers in participants ≥6 months to &lt;2 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to seroresponse rate to the Omicron XBB.1.5 strain in participants ≥2 to &lt;5 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to seroresponse rate to the Omicron XBB.1.5 strain titers in participants ≥6 months to &lt;2 years of age;SSA - Ph 2/3 selected dose, percentage of participants reporting adverse events;SSA - Ph 2/3 selected dose, percentage of participants reporting local reactions;SSA - Ph 2/3 selected dose, percentage of participants reporting serious adverse events;SSA - Ph 2/3 selected dose, percentage of participants reporting systemic events;SSB - noninferiority with respect to seroresponse rate to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - percentage of participants reporting adverse events;SSB - percentage of participants reporting serious adverse events;SSB - percentage of participants reporting systemic events;SSB - superiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding - geometric mean fold rise elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding - geometric mean titers elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding, percentage of participants reporting adverse events;SSC - Ph 1 dose finding, percentage of participants reporting serious adverse events;SSC - Ph 1 dose finding, percentage of participants reporting systemic events;SSC - Ph 1 dose finding - percentage of participants with seroresponse elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSD - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥5 to &lt;12 years of age;SSD - percentage of participants reporting adverse events;SSD - percentage of participants reporting serious adverse events;SSD - percentage of participants reporting systemic events;SSD - the ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥5 to &lt;12 years of age;SSE - noninferiority with respect to ratio of the geometric mean of SARS-CoV-2 reference strain-neutralizing titers in participants ≥5 to &lt;12 years of age;SSE - noninferiority with respect to seroresponse rate to the reference strain in participants ≥5 to &lt;12 years of age;SSE - percentage of participants reporting adverse events;SSE - percentage of participants reporting serious adverse events;SSE - percentage of participants reporting systemic events;Substudy A (SSA) - Ph 1 dose finding, percentage of participants reporting local reactions;Substudy B (SSB) - percentage of participants reporting local reactions;Substudy C (SSC) - Ph 1 dose finding, percentage of participants reporting local reactions;Substudy D (SSD) - percentage of participants reporting local reactions;Substudy E (SSE) - percentage of participants reporting local reactions
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="444774" class="table-">
                
                <td>Dec. 28, 2022, midnight</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            SSA - Ph 1 dose finding, percentage of participants reporting adverse events;SSA - Ph 1 dose finding, percentage of participants reporting serious adverse events;SSA - Ph 1 dose finding, percentage of participants reporting systemic events;SSA - Ph 2/3 selected dosed, superiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to seroresponse rate to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to the seroresponse rate to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSA - Ph 2/3 selected dose, percentage of participants reporting adverse events;SSA - Ph 2/3 selected dose, percentage of participants reporting local reactions;SSA - Ph 2/3 selected dose, percentage of participants reporting serious adverse events;SSA - Ph 2/3 selected dose, percentage of participants reporting systemic events;SSA - Ph 2/3 selected dose, superiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSB - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - percentage of participants reporting adverse events;SSB - percentage of participants reporting serious adverse events;SSB - percentage of participants reporting systemic events;SSB - Ph 2/3 selected dose, noninferiority with respect to seroresponse rate to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - Ph 2/3 selected dose, superiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSB - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSB - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding - geometric mean fold rise elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding - geometric mean titers elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding, percentage of participants reporting adverse events;SSC - Ph 1 dose finding, percentage of participants reporting serious adverse events;SSC - Ph 1 dose finding, percentage of participants reporting systemic events;SSC - Ph 1 dose finding - percentage of participants with seroresponse elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 2/3 selected dose - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain for participants ≥6 months to &lt;5 years of age;SSC - Ph 2/3 selected dose - percentage of participants reporting adverse events;SSC - Ph 2/3 selected dose, percentage of participants reporting local reactions;SSC - Ph 2/3 selected dose - percentage of participants reporting serious adverse events;SSC - Ph 2/3 selected dose, percentage of participants reporting systemic events;SSC - Ph 2/3 selected dose - the ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSD - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥5 to &lt;12 years of age;SSD - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain participants ≥5 to &lt;12 years of age;SSD - percentage of participants reporting adverse events;SSD - percentage of participants reporting serious adverse events;SSD - percentage of participants reporting systemic events;SSD - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥5 to &lt;12 years of age;SSD - the ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥5 to &lt;12 years of age;Substudy A (SSA) - Ph 1 dose finding, percentage of participants reporting local reactions;Substudy B (SSB) - percentage of participants reporting local reactions;Substudy C (SSC) - Ph 1 dose finding, percentage of participants reporting local reactions;Substudy D (SSD) - percentage of participants reporting local reactions
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            SSA - Ph 1 dose finding, percentage of participants reporting adverse events;SSA - Ph 1 dose finding, percentage of participants reporting serious adverse events;SSA - Ph 1 dose finding, percentage of participants reporting systemic events;SSA - Ph 2/3 selected dosed, superiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to seroresponse rate to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to the seroresponse rate to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSA - Ph 2/3 selected dose, percentage of participants reporting adverse events;SSA - Ph 2/3 selected dose, percentage of participants reporting local reactions;SSA - Ph 2/3 selected dose, percentage of participants reporting serious adverse events;SSA - Ph 2/3 selected dose, percentage of participants reporting systemic events;SSA - Ph 2/3 selected dose, superiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSB - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - percentage of participants reporting adverse events;SSB - percentage of participants reporting serious adverse events;SSB - percentage of participants reporting systemic events;SSB - Ph 2/3 selected dose, noninferiority with respect to seroresponse rate to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - Ph 2/3 selected dose, superiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSB - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSB - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding - geometric mean fold rise elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding - geometric mean titers elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding, percentage of participants reporting adverse events;SSC - Ph 1 dose finding, percentage of participants reporting serious adverse events;SSC - Ph 1 dose finding, percentage of participants reporting systemic events;SSC - Ph 1 dose finding - percentage of participants with seroresponse elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 2/3 selected dose - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain for participants ≥6 months to &lt;5 years of age;SSC - Ph 2/3 selected dose - percentage of participants reporting adverse events;SSC - Ph 2/3 selected dose, percentage of participants reporting local reactions;SSC - Ph 2/3 selected dose - percentage of participants reporting serious adverse events;SSC - Ph 2/3 selected dose, percentage of participants reporting systemic events;SSC - Ph 2/3 selected dose - the ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSD - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥5 to &lt;12 years of age;SSD - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain participants ≥5 to &lt;12 years of age;SSD - percentage of participants reporting adverse events;SSD - percentage of participants reporting serious adverse events;SSD - percentage of participants reporting systemic events;SSD - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥5 to &lt;12 years of age;SSD - the ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥5 to &lt;12 years of age;Substudy A (SSA) - Ph 1 dose finding, percentage of participants reporting local reactions;Substudy B (SSB) - percentage of participants reporting local reactions;Substudy C (SSC) - Ph 1 dose finding, percentage of participants reporting local reactions;Substudy D (SSD) - percentage of participants reporting local reactions
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="430886" class="table-">
                
                <td>Sept. 18, 2022, 3 a.m.</td>
                <td>usa</td>
                
                <td class="histvalue-container">
                    

        <p class="primary_outcome">
            SSA - Ph 1 dose finding, percentage of participants reporting adverse events;SSA - Ph 1 dose finding, percentage of participants reporting serious adverse events;SSA - Ph 1 dose finding, percentage of participants reporting systemic events;SSA - Ph 2/3 selected dosed, superiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;2 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to seroresponse rate to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;2 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to the the seroresponse rate to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;2 years of age;SSA - Ph 2/3 selected dose, percentage of participants reporting adverse events;SSA - Ph 2/3 selected dose, percentage of participants reporting local reactions;SSA - Ph 2/3 selected dose, percentage of participants reporting serious adverse events;SSA - Ph 2/3 selected dose, percentage of participants reporting systemic events;SSA - Ph 2/3 selected dose, superiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;2 years of age;SSB - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - percentage of participants reporting adverse events;SSB - percentage of participants reporting serious adverse events;SSB - percentage of participants reporting systemic events;SSB - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSB - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSB - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding - geometric mean fold rise elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding - geometric mean titers elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding, percentage of participants reporting adverse events;SSC - Ph 1 dose finding, percentage of participants reporting serious adverse events;SSC - Ph 1 dose finding, percentage of participants reporting systemic events;SSC - Ph 1 dose finding - percentage of participants with seroresponse elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 2/3 selected dose - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain for participants ≥6 months to &lt;5 years of age;SSC - Ph 2/3 selected dose - percentage of participants reporting adverse events;SSC - Ph 2/3 selected dose, percentage of participants reporting local reactions;SSC - Ph 2/3 selected dose - percentage of participants reporting serious adverse events;SSC - Ph 2/3 selected dose, percentage of participants reporting systemic events;SSC - Ph 2/3 selected dose - the ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSD - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥5 to &lt;12 years of age;SSD - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain participants ≥5 to &lt;12 years of age;SSD - percentage of participants reporting adverse events;SSD - percentage of participants reporting serious adverse events;SSD - percentage of participants reporting systemic events;SSD - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥5 to &lt;12 years of age;SSD - the ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥5 to &lt;12 years of age;Substudy A (SSA) - Ph 1 dose finding, percentage of participants reporting local reactions;Substudy B (SSB) - percentage of participants reporting local reactions;Substudy C (SSC) - Ph 1 dose finding, percentage of participants reporting local reactions;Substudy D (SSD) - percentage of participants reporting local reactions
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="primary_outcome validated">
            SSA - Ph 1 dose finding, percentage of participants reporting adverse events;SSA - Ph 1 dose finding, percentage of participants reporting serious adverse events;SSA - Ph 1 dose finding, percentage of participants reporting systemic events;SSA - Ph 2/3 selected dosed, superiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;2 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to seroresponse rate to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;2 years of age;SSA - Ph 2/3 selected dose, noninferiority with respect to the the seroresponse rate to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;2 years of age;SSA - Ph 2/3 selected dose, percentage of participants reporting adverse events;SSA - Ph 2/3 selected dose, percentage of participants reporting local reactions;SSA - Ph 2/3 selected dose, percentage of participants reporting serious adverse events;SSA - Ph 2/3 selected dose, percentage of participants reporting systemic events;SSA - Ph 2/3 selected dose, superiority with respect to ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;2 years of age;SSB - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥6 months to &lt;5 years of age;SSB - percentage of participants reporting adverse events;SSB - percentage of participants reporting serious adverse events;SSB - percentage of participants reporting systemic events;SSB - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSB - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSB - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding - geometric mean fold rise elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding - geometric mean titers elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 1 dose finding, percentage of participants reporting adverse events;SSC - Ph 1 dose finding, percentage of participants reporting serious adverse events;SSC - Ph 1 dose finding, percentage of participants reporting systemic events;SSC - Ph 1 dose finding - percentage of participants with seroresponse elicited by prophylactic bivalent BNT162b2 at each dose level given as a fourth dose in participants ≥6 months to &lt;5 years of age;SSC - Ph 2/3 selected dose - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain for participants ≥6 months to &lt;5 years of age;SSC - Ph 2/3 selected dose - percentage of participants reporting adverse events;SSC - Ph 2/3 selected dose, percentage of participants reporting local reactions;SSC - Ph 2/3 selected dose - percentage of participants reporting serious adverse events;SSC - Ph 2/3 selected dose, percentage of participants reporting systemic events;SSC - Ph 2/3 selected dose - the ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥6 months to &lt;5 years of age;SSD - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain in participants ≥5 to &lt;12 years of age;SSD - difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain participants ≥5 to &lt;12 years of age;SSD - percentage of participants reporting adverse events;SSD - percentage of participants reporting serious adverse events;SSD - percentage of participants reporting systemic events;SSD - ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥5 to &lt;12 years of age;SSD - the ratio of the geometric mean of SARS-CoV-2 Omicron BA.4/BA.5-neutralizing titers in participants ≥5 to &lt;12 years of age;Substudy A (SSA) - Ph 1 dose finding, percentage of participants reporting local reactions;Substudy B (SSB) - percentage of participants reporting local reactions;Substudy C (SSC) - Ph 1 dose finding, percentage of participants reporting local reactions;Substudy D (SSD) - percentage of participants reporting local reactions
        </p>
        
    
                </td>
            </tr>
            
        </tbody>
    </table>
</div>